Open AccessMaternal Sildenafil vs Placebo in Pregnant Women With Severe Early-Onset Fetal Growth Restriction
Author(s) -
Anouk Pels,
Jan Derks,
Ayten ElvanTaşpınar,
J. van Drongelen,
Marjon A. de Boer,
Hans Duvekot,
Judith van Laar,
Jim van Eyck,
Salwan AlNasiry,
Marieke Sueters,
Marinka S. Post,
Wes Onland,
Aleid G. Leemhuis,
Christiaaktgeboren,
Janus Christian Jakobsen,
Christian Gluud,
Ruben G. Duijnhoven,
A. Titia Lely,
Sanne J. Gordijn,
Wessel Ganzevoort
Publication year - 2020
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2020.5323
Subject(s) - medicine , sildenafil , gestational age , gestation , randomized controlled trial , obstetrics , placebo , intrauterine growth restriction , asphyxia , pediatrics , randomization , pregnancy , genetics , alternative medicine , pathology , biology
Key Points Question Does sildenafil reduce the risk of perinatal mortality or morbidity in children of pregnant women with severe early onset fetal growth restriction? Findings In this randomized clinical trial including 216 pregnant women, perinatal mortality or major morbidity was not statistically different and occurred in the offspring of 60.2% of participants allocated to sildenafil vs 54.2% of those allocated to placebo. Pulmonary hypertension occurred in 18.8% of neonates in the sildenafil group compared with 5.1% of neonates in the placebo group, which was statistically significantly different. Meaning These findings suggest that treatment of severe early onset fetal growth restriction by maternal sildenafil did not reduce the risk of perinatal mortality or major neonatal morbidity, but increased neonatal pulmonary hypertension was observed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom